<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296659</url>
  </required_header>
  <id_info>
    <org_study_id>IDD 10-09</org_study_id>
    <nct_id>NCT01296659</nct_id>
  </id_info>
  <brief_title>Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma</brief_title>
  <official_title>Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been&#xD;
      tested in combination with the standard of care chemotherapy for sarcoma as this study will.&#xD;
      We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated&#xD;
      and to determine a Phase 2 dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator left institution.&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define maximum tolerated dose (MTD)</measure>
    <time_frame>12-18 months</time_frame>
    <description>Defining the maximum tolerated dose (MTD) and recommended Phase II dose for the combination ridaforolimus and SOC chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 2 or higher side effects with the combined therapy.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Any evidence of antitumor activity--as measured by response rate (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>12-18 months</time_frame>
    <description>Ridaforolimus pharmacokinetics when given in combination with SOC chemotherapy. Limited PK for SOC chemotherapy when combined with ridaforlimus. We will measure change in concentration of Ridaforolimus when combined with chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>AIM Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ridaforolimus combined with docetaxel and gemcitabine (TG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy</description>
    <arm_group_label>AIM Arm</arm_group_label>
    <arm_group_label>TG Arm</arm_group_label>
    <other_name>deforolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced or metastatic soft tissue sarcoma with histological or cytological proven&#xD;
             disease. No more than 2 lines of chemotherapy in the metastatic setting in the dose&#xD;
             escalation phase, and no more than one line of prior therapy in the expansion phase.&#xD;
&#xD;
          -  ECOG performance status of ≤ 1&#xD;
&#xD;
          -  A minimum life expectancy &gt; 3 months&#xD;
&#xD;
          -  At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy&#xD;
             or radiotherapy and the first dose of ridaforolimus&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function (hemoglobin ≥ 9g/dl, absolute&#xD;
             neutrophil count [ANC] ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; bilirubin ≤ ULN;&#xD;
             alkaline phosphatase ≤ 2.5 x ULN; AST, ALT ≤ 2.5 x ULN; albumin ≥ 2.5mg/dL; creatinine&#xD;
             ≤ 1.5 x ULN)&#xD;
&#xD;
          -  Serum cholesterol ≤ 350 mg/dL and triglycerides ≤400 mg/dL&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to start of therapy and must use an approved contraceptive method as&#xD;
             appropriate from the time of screening until 30 days after the last dose of study&#xD;
             drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis.&#xD;
&#xD;
          -  Clinically significant unexplained bleeding within 28 days prior to entering the trial&#xD;
&#xD;
          -  Uncontrolled systemic vascular hypertension&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Newly diagnosed (within 3 months of enrollment) or poorly controlled type 1 or 2&#xD;
             diabetes&#xD;
&#xD;
          -  Have received &gt;350 mg/m2 total dose of Doxorubicin&#xD;
&#xD;
          -  Active infection requiring prescribed intervention&#xD;
&#xD;
          -  Other concurrent illness&#xD;
&#xD;
          -  Major surgery within 28 days before trial entry, or incompletely healed surgical&#xD;
             incision; minor surgery or procedures within 7 days&#xD;
&#xD;
          -  Previous anthracycline lifetime exposure more than 350 mg/m2 would exclude patient&#xD;
             form AIM Arm enrollment&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Known allergy to macrolide antibiotics&#xD;
&#xD;
          -  Concurrent treatment with medications that induce or inhibit cytochrome P450 (CYP3A).&#xD;
&#xD;
          -  Known history of HIV sero-positivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Mita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center at UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctrc.net</url>
    <description>Cancer Therapy &amp; Research Center's Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcoma</keyword>
  <keyword>Ridaforolimus</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>unresectable sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

